Financhill
Sell
46

UCBJY Quote, Financials, Valuation and Earnings

Last price:
$148.22
Seasonality move :
5.19%
Day range:
$147.55 - $149.44
52-week range:
$71.16 - $151.76
Dividend yield:
0.53%
P/E ratio:
37.32x
P/S ratio:
7.74x
P/B ratio:
9.21x
Volume:
17.1K
Avg. volume:
20.2K
1-year change:
47.95%
Market cap:
$56.3B
Revenue:
$6.7B
EPS (TTM):
$3.81

Analysts' Opinion

  • Consensus Rating
    No consensus rating exists at this time due to lack of analyst coverage.
  • Price Target Downside
    No price target exists because of limited analyst coverage.
  • Price Target Upside
    Similarly, at this time, analysts have not provided a price target so downside risk can't be assessed accurately at this time.

Fair Value

  • According to the consensus of 0 analysts, UCB SA has -- downside to fair value with a price target of -- per share.

UCBJY vs. S&P 500

  • Over the past 5 trading days, UCB SA has overperformed the S&P 500 by 6.22% suggesting its relative strength compared to the major market average is strong at this time.

Share Buyback

  • UCB SA does not have a share repurchase program in place at this time. The scale of a buyback program can materially affect share price and usually results in a higher earnings per share, all else being equal, when the share count drops.

Revenue Growth

  • UCB SA has grown year-over-year revenues for 0 quarters straight. In the most recent quarter UCB SA reported revenues of --.

Earnings Growth

  • UCB SA has grown year-over-year earnings for 0 quarters straight. In the most recent quarter UCB SA reported earnings per share of --.
Enterprise value:
52B
EV / Invested capital:
--
Price / LTM sales:
7.74x
EV / EBIT:
39.13x
EV / Revenue:
6.98x
PEG ratio (5yr expected):
0.13x
EV / Free cash flow:
44.57x
Price / Operating cash flow:
49.38x
Enterprise value / EBITDA:
25.74x
Gross Profit (TTM):
$5.2B
Return On Assets:
7.93%
Net Income Margin (TTM):
19.43%
Return On Equity:
13.88%
Return On Invested Capital:
10.75%
Operating Margin:
--
Trailing 12 Months Fiscal Quarters
Period Ending 2010-12-31 2011-12-31 2012-12-31 2011-12-31 2012-12-31
Income Statement
Revenue $4.3B $4.5B $4.5B -- --
Gross Profit $2.9B $3.1B $3.1B -- --
Operating Income $620.6M $591.1M $572.7M -- --
EBITDA $958M $933.3M $869.2M -- --
Diluted EPS $0.33 $0.83 $0.90 -- --
Period Ending 2021-06-30 2022-06-30 2023-06-30 2024-06-30 2025-06-30
Balance Sheet
Current Assets $3.5B $3.4B $3.3B $3.6B $6.2B
Total Assets $15.5B $17B $16.7B $16.8B $20.2B
Current Liabilities $2.8B $3B $2.9B $3B $4.6B
Total Liabilities $6.4B $7.7B $6.9B $7.2B $8.8B
Total Equity $9.1B $9.3B $9.8B $9.6B $11.4B
Total Debt -- -- -- -- --
Trailing 12 Months Fiscal Quarters
Period Ending 2024-01-10 2025-01-10 2025-01-10
Cash Flow Statement
Cash Flow Operations -- -- -- -- --
Cash From Investing -- -- -- -- --
Cash From Financing -- -- -- -- --
Free Cash Flow -- -- -- -- --
UCBJY
Sector
Market Cap
$56.3B
$28.1M
Price % of 52-Week High
97.67%
51.87%
Dividend Yield
0.53%
0%
Shareholder Yield
1.15%
-1.59%
1-Year Price Total Return
47.95%
-17.31%
Beta (5-Year)
0.684
0.495
Dividend yield:
0.53%
Annualized payout:
$0.73
Payout ratio:
-19.96%
Growth streak:
0 years

Technicals

8-day SMA
Buy
Level $143.29
200-day SMA
Buy
Level $113.87
Bollinger Bands (100)
Buy
Level 122.61 - 144.85
Chaikin Money Flow
Buy
Level 2.9M
20-day SMA
Buy
Level $141.11
Relative Strength Index (RSI14)
Buy
Level 63.46
ADX Line
Buy
Level 19.82
Williams %R
Sell
Level -12.0244
50-day SMA
Buy
Level $137.06
MACD (12, 26)
Buy
Level 2.23
25-day Aroon Oscillator
Buy
Level 8
On Balance Volume
Neutral
Level 2.9M

Financial Scores

Buy
Altman Z-Score (Annual)
Level (4.1008)
Buy
CA Score (Annual)
Level (0.1406)
Buy
Beneish M-Score (Annual)
Level (-2.3834)
Buy
Momentum Score
Level (9)
Buy
Ohlson Score
Level (-2.0121)
Buy
Piotroski F Score (Annual)
Level (8)
--
Quality Ratio Score
Level (--)
--
Fundamental Score
Level (--)

Revenue Forecast

Earnings per Share Forecast

Company Profile

UCB SA engages in the research and development of biopharmaceuticals products. It offers medicinal products such as briviact, keppra, vimpat, neupro, cimzia, nootropil, xyrem, xyzal, and zyrtec. The company was founded by Emmanuel Janssen on January 18, 1928 and is headquartered in Brussels, Belgium.

Stock Forecast FAQ

In the current month, UCBJY has received 0 Buy ratings 0 Hold ratings, and 0 Sell ratings. The UCBJY average analyst price target in the past 3 months is --.

  • Where Will UCB SA Stock Be In 1 Year?

    According to analysts, the consensus estimate is that UCB SA share price will drop to -- per share over the next 12 months.

  • What Do Analysts Say About UCB SA?

    Analysts are divided on their view about UCB SA share price and where it will be in the next 12 months. The majority of analysts rate the stock a Buy. However, a smaller subset of analysts suggest that UCB SA is a Sell and believe this share price will rise from its current level to --.

  • What Is UCB SA's Price Target?

    The price target for UCB SA over the next 1-year time period is forecast to be -- according to 0 Wall Street analysts, 0 of them rate the stock a Buy, 0 rate the stock a Sell, and 0 analysts rate the stock a Hold.

  • Is UCBJY A Buy, Sell Or Hold?

    According to Wall Street analysts, the consensus rating for UCB SA is a --. 0 of 0 analysts rate the stock a -- at this time.

  • How Can I Buy Shares Of UCBJY?

    You can purchase shares of UCB SA via an online brokerage firm such as TD Ameritrade.com, thinkorswim.com, e-trade.com, or Schwab.com. Many other digital online brokerages exist such as RobinHood and Webull where you can purchase UCB SA shares.

  • What Is The UCB SA Share Price Today?

    UCB SA was last trading at $148.22 per share. This represents the most recent stock quote for UCB SA. Yesterday, UCB SA closed at $148.22 per share.

  • How To Buy UCB SA Stock Online?

    In order to purchase UCB SA stock online, open a brokerage account, deposit funds into the account, and select an order type to purchase shares whether it be market or limit.

SEE THE 1% OF STOCKS YOU NEED TO OWN FOR MASSIVE RETURNS

GET BETTER TRADE IDEAS

Popular

Will The Magnificent 7 Stocks Go Up This Year?
Will The Magnificent 7 Stocks Go Up This Year?

2025 was another banner year for the Magnificent Seven stocks,…

Why Did Planet Labs Stock Rally So Much?
Why Did Planet Labs Stock Rally So Much?

Satellite imaging startup Planet Labs (NYSE:PL), after years of disappointing…

Why Did Stan Druckenmiller Sell Broadcom Stock?
Why Did Stan Druckenmiller Sell Broadcom Stock?

In Q3, legendary macro investor Stan Druckenmiller sold his entire…

Stock Ideas

Buy
52
Is NVDA Stock a Buy?

Market Cap: $4.5T
P/E Ratio: 63x

Buy
65
Is GOOG Stock a Buy?

Market Cap: $4T
P/E Ratio: 41x

Buy
51
Is GOOGL Stock a Buy?

Market Cap: $4T
P/E Ratio: 41x

Alerts

Buy
100
ATGL alert for Jan 10

Alpha Technology Group Ltd. [ATGL] is up 47.05% over the past day.

Buy
71
NAIL alert for Jan 10

Direxion Daily Homebuilders & Supplies Bull 3X Shs [NAIL] is up 18.52% over the past day.

Buy
54
LGIH alert for Jan 10

LGI Homes, Inc. [LGIH] is up 13.81% over the past day.

THE #1 STOCK ANALYSIS TOOL
TO MAKE SMARTER BUY AND SELL DECISIONS

Show me the best stock